Patents Assigned to Astex Therapeutics Limited
  • Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
    Patent number: 12077526
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: September 3, 2024
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven Howard, Benjamin David Cons, Jeffrey David St. Denis, Rhian Sara Holvey, Guillaume François Parra, Kim Louise Hirst, Isabelle Anne Lemasson, David John Nash, James Daniel Osborne, Jonas Calleja Priede, Nicholas Paul Richards, Aaron Michael Dumas, Brian Christopher Bishop, David Parry-Jones, Meenakshi Sundaram Shanmugham, Darren James Dixon, Matthew James Gaunt
  • Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
    Patent number: 12071429
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 27, 2024
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20240199607
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: November 1, 2023
    Publication date: June 20, 2024
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne WOOLFORD, Steven HOWARD, Ildiko Maria BUCK, Gianni CHESSARI, Christopher Norbert JOHNSON, Emiliano TAMANINI, James Edward Harvey DAY, Elisabetta CHIARPARIN, Thomas Daniel HEIGHTMAN, Martyn FREDERICKSON, Charlotte Mary GRIFFITHS-JONES
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11866428
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: January 9, 2024
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne Woolford, Steven Howard, Ildiko Maria Buck, Gianni Chessari, Christopher Norbert Johnson, Emiliano Tamanini, James Edward Harvey Day, Elisabetta Chiarparin, Thomas Daniel Heightman, Martyn Frederickson, Charlotte Mary Griffiths-Jones
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM
    Publication number: 20230278989
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: January 25, 2023
    Publication date: September 7, 2023
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20230227450
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 20, 2023
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11643410
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 9, 2023
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
    Patent number: 11603367
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: March 14, 2023
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven Howard, Jeffrey David St. Denis, Charlotte Mary Griffiths-Jones, Steven Douglas Hiscock, Alan Richard Burns, David Cousin, Kim Louise Hirst, James Daniel Osborne, Jonas Calleja Priede, Aaron Michael Dumas, Brian Christopher Bishop, David Parry-Jones, Jeremy Peter Scott, Meenakshi Sundaram Shanmugham, Peter Richard Mullens, Darren James Dixon, Matthew James Gaunt
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20220204503
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 30, 2022
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20220106287
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: April 12, 2021
    Publication date: April 7, 2022
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
    Patent number: 11261171
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 1, 2022
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Combination of isoindolinone derivatives with SGI-110
    Patent number: 11236047
    Abstract: The invention provides a combination comprising: (i) a compound of formula (Io): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 1, 2022
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, John Francis Lyons
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11225476
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: January 18, 2022
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20210276984
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 9, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Ether linked triazoles as NRF2 activators
    Patent number: 11059816
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 13, 2021
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, ASTEX THERAPEUTICS LIMITED
    Inventors: Anthony William James Cooper, Nicole Cathleen Goodwin, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Jeffrey K. Kerns, Hendrika Maria Gerarda Willems, Hongxing Yan
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20210122749
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 29, 2021
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne WOOLFORD, Steven HOWARD, Ildiko Maria BUCK, Gianni CHESSARI, Christopher Norbert JOHNSON, Emiliano TAMANINI, James Edward Harvey DAY, Elisabetta CHIARPARIN, Thomas Daniel HEIGHTMAN, Martyn FREDERICKSON, Charlotte Mary GRIFFITHS-JONES
  • Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
    Patent number: 10981898
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: April 20, 2021
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM
    Publication number: 20210101887
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 8, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20200325134
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: February 19, 2020
    Publication date: October 15, 2020
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110
    Publication number: 20200207711
    Abstract: The invention provides a combination comprising: (i) a compound of formula (Io): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.
    Type: Application
    Filed: March 28, 2018
    Publication date: July 2, 2020
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, John Francis LYONS